Thread by @MrMikeInvesting

$ADXS - Advaxis Immunotherapies DD Thread 🔥
Produced by - @MrMikeInvesting

Company Overview
• Advaxis Inc engages in the discovery,development, commercialization of cancer immunotherapies
• Advaxis has 145M shares Outstanding and 140M of them are public float
•This company was founded on 2002 in NJ and its HQ is located in Princeton,NJ
Page 1

Clinical Pipeline
-ADXS-HOT: Off-the-shelf, tumor type-specific constructs
-ADXS-503 in NSCLC in Phase 1/2 study
-ADXS-504 in prostate cancer scheduled,enter clinic in Q3 2021
-ADXS-HPV HPV+cancers
Upcoming Milestones
ADXS-504: Clinical trial initiation + data readout
Page 2

Merger Agreements
• Advaxis has Entered into a merger agreement with Biosight
• The combined company is expected to have approximately $50M from the merger in Q4 2021
• Advaxis will be renamed Biosight Therapeutics and will trade on the Nasdaq, ticker symbol BSTX
Page 3

Advaxis Experienced Management
Kenneth A. Berlin/CEO
Worked at: Veridex,J&J,Rosetta Genomics,Ortha Clinical
Dr. Robert Petit
Worked at: Biomarin,Proteolix,Sunesis,Bristol Myers,Ncolytics,Mellas
Dr. Andres Gutierrez/CMO
Worked at: Aesgen, MGI, Pharmacia, Bristol Myers
Page 4

Advaxis has a total of 57 institutional owners,56 long,1 short
Institutions own 7% of the total shares which= $10M
• Many major institutions are invested into Advaxis
• Some include:
• Morgan Stanley
• Blackrock
• Wells Fargo
• Bank of America
fintel.io/so/us/adxs
Page 5

Insider Ownership
• Advaxis has a total of 21 insider Owners
• Insider own .42% of the total shares and this equates to 605,614 shares
• As the merger comes closer insider trading should significantly ramp up
Page 6

I would like to now conclude this DD Thread on Advaxis Immunotherapies
Price Targets 🎯
Short Term ($1-$2.5)
Long Term ($4-$7)
@Ultra_Calls
@RadioSilentplay
@LadeBackk
Page 7